RT Journal Article
SR Electronic
T1 Rare coding variation illuminates the allelic architecture, risk genes, cellular expression patterns, and phenotypic context of autism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.20.21267194
DO 10.1101/2021.12.20.21267194
A1 Fu, Jack M.
A1 Satterstrom, F. Kyle
A1 Peng, Minshi
A1 Brand, Harrison
A1 Collins, Ryan L.
A1 Dong, Shan
A1 Klei, Lambertus
A1 Stevens, Christine R.
A1 Cusick, Caroline
A1 Babadi, Mehrtash
A1 Banks, Eric
A1 Collins, Brett
A1 Dodge, Sheila
A1 Gabriel, Stacey B.
A1 Gauthier, Laura
A1 Lee, Samuel K.
A1 Liang, Lindsay
A1 Ljungdahl, Alicia
A1 Mahjani, Behrang
A1 Sloofman, Laura
A1 Smirnov, Andrey
A1 Barbosa, Mafalda
A1 Brusco, Alfredo
A1 Chung, Brian H.Y.
A1 Cuccaro, Michael L.
A1 Domenici, Enrico
A1 Ferrero, Giovanni Battista
A1 Gargus, Jay J.
A1 Herman, Gail E.
A1 Hertz-Picciotto, Irva
A1 Maciel, Patricia
A1 Manoach, Dara S.
A1 Passos-Bueno, Maria Rita
A1 Persico, Antonio M.
A1 Renieri, Alessandra
A1 Tassone, Flora
A1 Trabetti, Elisabetta
A1 Campos, Gabriele
A1 Chan, Marcus C.Y.
A1 Fallerini, Chiara
A1 Giorgio, Elisa
A1 Girard, Ana Cristina
A1 Hansen-Kiss, Emily
A1 Lee, So Lun
A1 Lintas, Carla
A1 Ludena, Yunin
A1 Nguyen, Rachel
A1 Pavinato, Lisa
A1 Pericak-Vance, Margaret
A1 Pessah, Isaac
A1 Riberi, Evelise
A1 Schmidt, Rebecca
A1 Smith, Moyra
A1 Souza, Claudia I.C.
A1 Trajkova, Slavica
A1 Wang, Jaqueline Y.T.
A1 Yu, Mullin H.C.
A1 The Autism Sequencing Consoritum (ASC)
A1 Broad Institute Center for Common Disease Genomics (Broad-CCDG)
A1 iPSYCH-BROAD Consortium
A1 Cutler, David J.
A1 De Rubeis, Silvia
A1 Buxbaum, Joseph D.
A1 Daly, Mark J.
A1 Devlin, Bernie
A1 Roeder, Kathryn
A1 Sanders, Stephan J.
A1 Talkowski, Michael E.
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.20.21267194.abstract
AB Individuals with autism spectrum disorder (ASD) or related neurodevelopmental disorders (NDDs) often carry disruptive mutations in genes that are depleted of functional variation in the broader population. We build upon this observation and exome sequencing from 154,842 individuals to explore the allelic diversity of rare protein-coding variation contributing risk for ASD and related NDDs. Using an integrative statistical model, we jointly analyzed rare protein-truncating variants (PTVs), damaging missense variants, and copy number variants (CNVs) derived from exome sequencing of 63,237 individuals from ASD cohorts. We discovered 71 genes associated with ASD at a false discovery rate (FDR) ≤ 0.001, a threshold approximately equivalent to exome-wide significance, and 183 genes at FDR ≤ 0.05. Associations were predominantly driven by de novo PTVs, damaging missense variants, and CNVs: 57.4%, 21.2%, and 8.32% of evidence, respectively. Though fewer in number, CNVs conferred greater relative risk than PTVs, and repeat-mediated de novo CNVs exhibited strong maternal bias in parent-of-origin (e.g., 92.3% of 16p11.2 CNVs), whereas all other CNVs showed a paternal bias. To explore how genes associated with ASD and NDD overlap or differ, we analyzed our ASD cohort alongside a developmental delay (DD) cohort from the deciphering developmental disorders study (DDD; n=91,605 samples). We first reanalyzed the DDD dataset using the same models as the ASD cohorts, then performed joint analyses of both cohorts and identified 373 genes contributing to NDD risk at FDR ≤ 0.001 and 662 NDD risk genes at FDR ≤ 0.05. Of these NDD risk genes, 54 genes (125 genes at FDR ≤ 0.05) were unique to the joint analyses and not significant in either cohort alone. Our results confirm overlap of most ASD and DD risk genes, although many differ significantly in frequency of mutation. Analyses of single-cell transcriptome datasets showed that genes associated predominantly with DD were strongly enriched for earlier neurodevelopmental cell types, whereas genes displaying stronger evidence for association in ASD cohorts were more enriched for maturing neurons. The ASD risk genes were also enriched for genes associated with schizophrenia from a separate rare coding variant analysis of 121,570 individuals, emphasizing that these neuropsychiatric disorders share common pathways to risk.Competing Interest StatementB.M.N. is a member of the scientific advisory board at Deep Genomics and consults for Biogen, Camp4 Therapeutics Corporation, Takeda Pharmaceutical, and Biogen. C.M. Freitag has been a consultant to Desitin and Roche and receives royalties for books on ASD, ADHD, and MDD.Funding StatementThis work was supported by grants from the Simons Foundation for Autism Research Initiative (SSC-ASC Genomics Consortium #574598 to S.J.S., #575097 to B.D. and K.R., #573206 to M.E.T. and M.J.D., #571009 to J.D.; the SPARK project and SPARK analysis projects #606362 and #608540 to M.E.T., M.J.D., J.B., B.D., K.R., S.J.S.; SFARI #402281 to S.J.S., M.W.S., B.D., and K.R. and #647371 to S.J.S.), NHGRI (HG008895 to M.J.D., S.G., M.E.T.), NIMH (MH115957 to M.E.T., MH111658 and MH057881 to B.D., MH111661 and MH100233 to J.D.B., R01 MH109900 to K.R., MH111660 to M.J.D., and MH111662 and MH100027 to S.J.S. and M.W.S.), NICHD (HD081256 to M.E.T.), AMED (JP21WM0425007 to N.O). and the Seaver Foundation. J.M.F. was supported by an Autism Speaks Postdoctoral Fellowship and R.L.C. was supported by NSF GRFP #2017240332.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study Protocol 2012P001018, The Study of Novel Autism Genes and Other Neurodevelopmental Disorders (March 12, 2021) Study Protocol 2013P000323, Genomic Studies of Human Neurodevelopment (September 07, 2018) Protocols undergo annual continuing review by the Mass General Brigham Human Research Committee (MGBHRC) Institutional Review Board (IRB) of Mass General Brigham. Mass General Brigham IRB, Mass General Brigham, 399 Revolution Drive, Suite 710, Somerville, MA 02145. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are deposited at: Repository/DataBank Accession: NHGRI AnVIL Accession ID: phs000298 Databank URL: https://anvilproject.org/data Repository/DataBank Accession: Simons Foundation for Autism Research Initiative SFARIbase Accession ID: SPARK/Regeneron/SPARK_WES_2/ Databank URL: https://www.sfari.org/resource/spark/